title: Spironolactone therapy in heart failure patients with chronic kidney disease.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Lopes
authors.forename: Patricia
authors.initials: P
authors.lastname: Lourenco
authors.forename: Joana
authors.initials: J
authors.lastname: Mascarenhas
authors.forename: Ana
authors.initials: A
authors.lastname: Azevedo
authors.forename: Paulo
authors.initials: P
authors.lastname: Bettencourt
mesh_terms: D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D006333:Heart Failure / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006947:Hyperkalemia / Q000097:blood / Q000139:chemically induced*; D007674:Kidney Diseases / Q000097:blood / Q000150:complications*; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects*; D011188:Potassium / Q000097:blood; D013148:Spironolactone / Q000009:adverse effects*
chemical_list: D015415:Biomarkers; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D003404:Creatinine; D011188:Potassium